Resources
89 Results (showing 21 - 30)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 2/28/2023 (updated 3/27/2024)
This study's objective was to develop and validate a survey tool to assess emergency department physician attitudes, clinical practice, and willingness to perform opiate harm reduction interventions. After surveying physicians, most showed they were willing to provide necessary interventions, while few do perform them. Although there was an increased willingness to perform the interventions, a disparity remains.
Posted 1/31/2023 (updated 3/27/2024)
These guides from the Substance Abuse and Mental Health Services Administration (SAMHSA) highlights strategies for behavioral health and housing providers to conduct outreach and engage with individuals experiencing homelessness, initiate use of behavioral health treatment as they wait to receive stable housing and retain them in their recovery efforts once housed.
Posted 1/24/2023 (updated 3/27/2024)
This webinar will introduce the newest RCORP program cohorts to the RCOEs, Fletcher Group, University of Rochester, and University of Vermont. These three cooperative agreements are charged with supporting the identification, translation, dissemination, and implementation of evidence-based programs and best practices, in addition to providing specialized TA to RCORP recipients and other rural providers.
Posted 12/20/2022 (updated 3/27/2024)
The Centers for Medicare & Medicaid Services (CMS) recently released the Calendar Year (CY) 2023 Physician Fee Schedule. This rule makes policy updates which may increase accessibility of behavioral health services and telehealth services in rural areas. CMS subject matter experts from the Hospital and Ambulatory Policy Group (HAPG) presented on the behavioral health and telehealth updates in the rule during the webinar held on Wednesday, December 14, 2022.
Posted 10/3/2022 (updated 3/27/2024)
Nitazenes are a novel group of powerful illicit synthetic opioids derived from 2-benzylbenzimidazole that have been linked to overdose deaths in several states. Nitazenes were created as a potential pain reliever medication nearly 60 years ago but have never been approved for use in the United States. Laboratory test results indicate that the potency of certain nitazene analogs (e.g., isotonitazene, protonitazene, and etonitazene) greatly exceeds that of fentanyl, whereas the potency of the analog metonitazene is similar to fentanyl.
Posted 9/28/2022 (updated 3/27/2024)
Last week, the U.S. Department of Health & Human Services (HHS) introduced the Roadmap for Behavioral Health Integration, to advance the White House Strategy to Address our National Mental Health Crisis announced earlier this year.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 8/23/2022 (updated 3/27/2024)
In this cross-sectional, multistate study of rural communities, 79% of people using drugs reported past-30-day methamphetamine use; nonfatal overdose was greatest in people using both methamphetamine and opioids (22%) vs opioids alone (14%), or methamphetamine alone (6%). People using both substances reported the least access to treatment; only 17% of those using methamphetamine alone had naloxone.